TrialThe New England journal of medicine2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
531 papers cite itlatest 60 shown
this paperpooled ittrialcites it